The UAE is all prepared to host yet another COVID-19 vaccine candidate trial after it successfully conducted the phase 3 trials Sinopharm CNBG’s COVID-19 vaccine candidate from China.
Abu Dhabi’s Department of Health will collaborate with the Abu Dhabi Health Services Company (SEHA) to conduct the trials for the Russian COVID-19 vaccine candidate named Sputnik V under the supervision of the UAE’s Ministry of Health and Prevention.
Data published about the first two stages of the trial for the vaccine candidate in the leading medical journal The Lancet revealed that the cure induced a stable humoral and cellular immune response in all (100 percent) volunteers with no serious adverse events recorded.
Volunteers for the trial will be medically supervised for 90 days after taking the vaccine.
Sheikh Abdulla bin Mohamed Al Hamed Chairman Department of Health – Abu Dhabi
“Hosting a second Phase 3 COVID-19 vaccine trials in Abu Dhabi reaffirms our enduring commitment to collaborating on global solutions to the challenges this pandemic has presented.
“Thanks to our world-class healthcare infrastructure, the strength of our research ecosystem, and the community’s spirit of volunteerism, Abu Dhabi is an attractive prospect for those seeking to advance scientific discovery.
Speaking on the UAE trials for the Gamaleya developed vaccine candidate, Russian Direct Investment Fund CEO Kirill Dmitriev shared that “The UAE has demonstrated one of the most advanced approaches in the world to combat the coronavirus pandemic. We are pleased to commence the trials and we look forward to announcing in due course the registration process for volunteers. As part of the Phase 3 trials of the vaccine, we are planning to expand in several other countries over the coming months, and we are delighted that Abu Dhabi will be the first place in which we do so in the Middle East.”
The interim results for the trials conducted in Russia and other countries including the UAE are expected to be released before the end of November.
